← All Conditions ← Immune Overview

Graft-Versus-Host Disease (GVHD)

★ CMTO Exam Focus

GVHD is a major complication following allogeneic hematopoietic stem cell or bone marrow transplantation, occurring when donor T lymphocytes recognize the recipient's tissues as foreign and mount an immune attack against the host's skin, gastrointestinal tract, and liver. Acute GVHD develops within the first 100 days post-transplant; chronic GVHD occurs after 100 days and resembles an autoimmune process. Severe acute GVHD has survival rates as low as 5%.

Recognition

  • Cutaneous: Pruritic maculopapular rash starting on palms and soles (often the first clinical sign). Blisters and ulcerations in severe cases. Chronic GVHD can produce scleroderma-like skin hardening
  • GI distress: Nausea, anorexia, profuse watery diarrhea, abdominal pain. GI bleeding is an ominous sign
  • Hepatic: Jaundice, hepatomegaly (enlarged liver), elevated liver enzymes
  • Systemic: Fever, chills, muscle aches, profound fatigue
  • Three requirements for GVHD: Graft must contain immunocompetent cells, host must have antigens not present in the donor, and host must be unable to destroy the transplanted cells
  • Timeline: Acute (<100 days post-transplant) vs. chronic (>100 days)

MT Relevance

  • Bleeding precautions are critical: Bone marrow suppression causes thrombocytopenia with high bruising and bleeding risk. Avoid all deep, aggressive, or friction-based techniques
  • Strict institutional hygiene protocols: These clients are profoundly immunocompromised. Postpone sessions if the therapist has any active illness, even a mild cold
  • Acute stage: Work should be limited to gentle supportive contact — holding or light stroking only
  • Nitrile or vinyl gloves may be required by facility protocols
  • Skin integrity: Inspect for rashes, blisters, ulcerations, and scleroderma-like changes before treatment. All skin lesions are local contraindications
  • Chemotherapy-induced peripheral neuropathy: Numbness or paresthesia from pre-transplant chemotherapy. Assess sensation before applying pressure

Required Actions

  • GI bleeding (blood in stool, melena, or hematemesis) is an ominous sign requiring immediate medical attention — do not treat
  • Fever indicates active immune response — systemic contraindication. Do not treat
  • Coordinate with the medical team before initiating any massage program for a GVHD patient. Treatment must be integrated with the transplant team's care plan

Key Takeaways

  • Bleeding precautions are critical: bone marrow suppression causes thrombocytopenia with high bruising risk.
  • Follow strict institutional hygiene protocols. Postpone sessions if the therapist has any active illness.
  • Acute stage work is limited to gentle supportive holding or light stroking only.
  • GI bleeding is an ominous sign requiring immediate medical attention.
  • Severe acute GVHD has survival rates as low as 5%. The maculopapular rash on palms and soles is often the first clinical sign.

Sources

  • Rattray, F., & Ludwig, L. (2000). Clinical massage therapy: Understanding, assessing and treating over 70 conditions. Talus Incorporated.
  • Werner, R. (2012). A massage therapist's guide to pathology (5th ed.). Lippincott Williams & Wilkins.
  • Norris, T. L. (2019). Porth's essentials of pathophysiology (5th ed.). Wolters Kluwer.